- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: c-SN6j | TRC-105 | TRC105
Compound class: Antibody
Comment: Carotuximab is an investigational, chimeric mouse/human anti-endoglin monoclonal antibody, with potential immunomodulatory and antineoplastic action.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent US8221753, and to the antibody designated TR105 (c-SN6j) therein .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Carotuximab (using research code TRC105) is being evaluated in a number of Phase II clinical trials, against a range of solid tumour types. Click here to link to the Phase II carotuximab trials listed by ClinicalTrials.gov.|